Werewolf Therapeutics Appoints Meeta Chatterjee, Ph.D., to its Board of Directors

October 28, 2021

Over 30 years of broad strategic and operational experience in pharmaceutical research and development, mergers and acquisition evaluation, in-licensing, and externalization activities

April 24, 2024

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

WATERTOWN, Mass., April 24, 2024 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More

April 23, 2024

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

WATERTOWN, Mass., April 23, 2024 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More

April 5, 2024

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

WATERTOWN, Mass., April 05, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More

Share this article: